Biotech Values

[mcbio]

VRTX

Through 12 weeks, adverse event rates were 51.2 percent for the pooled VX-509 treatment group compared to 38.0 percent for those who received placebo, and the majority of adverse events observed in the study were mild to moderate.

Would be curious to know how that 51% adverse event rate stacks up to the JAK competition.

Infections occurred in 22.0 percent of people in the pooled VX-509 treatment group compared to 15.5 percent in the placebo group, and serious infections occurred in 2.8 percent of people in the VX-509 group compared to 1.4 percent for placebo.

Is an infection rate of 22% cause for potential concern? And, although it may ultimately be a relatively small percentage overall, what about the fact that serious infections occurred at double the rate in the VX-509 arm vs. placebo?